365 related articles for article (PubMed ID: 31692111)
41. Human skin collagenase in recessive dystrophic epidermolysis bullosa. Purification of a mutant enzyme from fibroblast cultures.
Stricklin GP; Welgus HG; Bauer EA
J Clin Invest; 1982 Jun; 69(6):1373-83. PubMed ID: 6282934
[TBL] [Abstract][Full Text] [Related]
42. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
43. [Renal Transplantation in a patient with Recessive Dystrophic Epidermolysis Bullosa: a case report].
Saad EJ; Albertini RA; Chiurchiu C; Massari PU; De la Fuente JL
Rev Fac Cien Med Univ Nac Cordoba; 2018 Mar; 75(1):46-49. PubMed ID: 30130485
[TBL] [Abstract][Full Text] [Related]
44. Recessive Dystrophic Epidermolysis Bullosa and Pregnancy.
Boria F; Maseda R; Martín-Cameán M; De la Calle M; de Lucas R
Actas Dermosifiliogr (Engl Ed); 2019; 110(1):50-52. PubMed ID: 29203033
[TBL] [Abstract][Full Text] [Related]
45. Recessive dystrophic epidermolysis bullosa skin displays a chronic growth-activated immunophenotype. Implications for carcinogenesis.
Smoller BA; McNutt NS; Carter DM; Gottlieb AB; Hsu A; Krueger J
Arch Dermatol; 1990 Jan; 126(1):78-83. PubMed ID: 1688702
[TBL] [Abstract][Full Text] [Related]
46. Recessive dystrophic epidermolysis bullosa-associated squamous-cell carcinoma: an enigmatic entity with complex pathogenesis.
Rodeck U; Uitto J
J Invest Dermatol; 2007 Oct; 127(10):2295-6. PubMed ID: 17853916
[TBL] [Abstract][Full Text] [Related]
47. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
[TBL] [Abstract][Full Text] [Related]
48. [A rare cause of AA amyloidosis: Hereditary epidermolysis bullosa].
Chaabouni R; Amouri M; Chaari C; Bouattour Y; Sellami K; Bahloul Z; Boudawara T; Turki H
Nephrol Ther; 2022 Apr; 18(2):136-139. PubMed ID: 34838485
[TBL] [Abstract][Full Text] [Related]
49. The potential of gene therapy for recessive dystrophic epidermolysis bullosa.
Subramaniam KS; Antoniou MN; McGrath JA; Lwin SM
Br J Dermatol; 2022 Apr; 186(4):609-619. PubMed ID: 34862606
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa.
Feinstein JA; Bruckner AL; Chastek B; Anderson A; Roman J
Orphanet J Rare Dis; 2022 Sep; 17(1):367. PubMed ID: 36175960
[TBL] [Abstract][Full Text] [Related]
51. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
[TBL] [Abstract][Full Text] [Related]
52. Malignant melanoma and a squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Chorny JA; Shroyer KR; Golitz LE
Arch Dermatol; 1993 Sep; 129(9):1212. PubMed ID: 8363416
[No Abstract] [Full Text] [Related]
53. Natural gene therapy in dystrophic epidermolysis bullosa.
van den Akker PC; Nijenhuis M; Meijer G; Hofstra RM; Jonkman MF; Pasmooij AM
Arch Dermatol; 2012 Feb; 148(2):213-6. PubMed ID: 22004882
[TBL] [Abstract][Full Text] [Related]
54. Structural variations in anchoring fibrils in dystrophic epidermolysis bullosa: correlation with type VII collagen expression.
McGrath JA; Ishida-Yamamoto A; O'Grady A; Leigh IM; Eady RA
J Invest Dermatol; 1993 Apr; 100(4):366-72. PubMed ID: 8454899
[TBL] [Abstract][Full Text] [Related]
55. [Cutaneous squamous cell carcinomas: a complication of severe forms of hereditary epidermolysis bullosa].
Bourrat E
Soins; 2023 Nov; 68(880):36-38. PubMed ID: 37931996
[TBL] [Abstract][Full Text] [Related]
56. Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation.
Bodemer C; Tchen SI; Ghomrasseni S; Séguier S; Gaultier F; Fraitag S; de Prost Y; Godeau G
J Invest Dermatol; 2003 Aug; 121(2):273-9. PubMed ID: 12880418
[TBL] [Abstract][Full Text] [Related]
57. Verruciform xanthoma developing in recessive dystrophic epidermolysis bullosa: A sheep in wolf's clothing.
Curto-Barredo L; Segura S; Barranco C; Bellosillo B; Lloreta J; Toll A; Sanmartín O; Pujol RM
Am J Dermatopathol; 2014 Jun; 36(6):506-9. PubMed ID: 23676320
[TBL] [Abstract][Full Text] [Related]
58. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
[TBL] [Abstract][Full Text] [Related]
59. "Sporadic" dystrophic epidermolysis bullosa: a new dominant or mitis recessive mutation?
Vaccaro M; Moretti G; Guarneri F; Cannavò S; Magaudda L
Eur J Dermatol; 2000 Aug; 10(6):436-8. PubMed ID: 10980463
[TBL] [Abstract][Full Text] [Related]
60. Inpatient management of children with recessive dystrophic epidermolysis bullosa: A review.
Li AW; Prindaville B; Bateman ST; Gibson TE; Wiss K
Pediatr Dermatol; 2017 Nov; 34(6):647-655. PubMed ID: 28944966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
